Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Compugen Announces Discovery of Two Drug Target Candidates for mAb Cancer Therapy

Published: Tuesday, March 05, 2013
Last Updated: Tuesday, March 05, 2013
Bookmark and Share
Targets are expressed in multiple cancers and have a distinct mode of action inhibiting two key immune cell subsets.

Compugen Ltd. has announced the discovery and initial validation of two new drug target candidates for monoclonal antibody (mAb) cancer therapy.

These new candidates have been shown to be expressed in multiple types of tumors and were shown to have an immunomodulatory activity in affecting both innate and adaptive immune responses, thus providing the potential for an efficient and targeted approach in cancer treatment.

By offering a different mode of action from Compugen's other immune checkpoint candidates, these molecules further broaden the scope of the Company's Pipeline Program for monoclonal antibody treatment of cancer.

In recent in vitro studies, both of these immune checkpoint molecules have shown distinct activity inhibiting two key subtypes of immune cells, Natural Killer (NK) cells and T cells.

These key immune cell subtypes act to recognize and kill tumor cells and have critical roles in the response of the immune system to tumor development.

Antibodies directed against and blocking each of these immune checkpoints could remove their inhibitory effect on T cells and NK cells, thus enhancing the anti-tumor activity of these pivotal immune cell subsets.

Therefore, agents targeting these checkpoint molecules hold great promise for efficient cancer immunotherapy and long-lived tumor destruction.

Recent protein expression studies for these two Compugen-discovered molecules indicate enhanced expression in a wide variety of cancers with high unmet medical need. These include lung, ovarian, breast, colorectal, gastric and liver cancer.

Hence, in addition to their potential utility in cancer immunotherapy, which aims to stimulate the patient’s own immune system to eliminate cancer cells, these two molecules also have therapeutic potential as drug targets for direct cancer mAb therapy, whereby monoclonal antibodies directed against these targets would directly destroy the cancer cells.

Dr. Anat Cohen-Dayag, President and CEO of Compugen, stated, “It is increasingly evident that the blockade of immune checkpoints is among the most promising approaches to activate therapeutic anti-tumor immunity. Therefore, we are very pleased with the addition of the two immune checkpoint targets being disclosed today, each of which acts on both arms of the immune system."

Dr. Cohen-Dayag continued, "These two molecules broaden Compugen's oncology pipeline, thus potentially providing differentiated and effective solutions for multiple forms of cancer. In this respect, we recently reported that CGEN-15001, an Fc fusion protein based on the Compugen-discovered CGEN-15001T immune checkpoint target, promotes inducible regulatory T cells (iTregs) in addition to its inhibitory effect on T cells. Therefore, an antibody directed against and blocking CGEN-15001T has the potential to eliminate the inhibitory effect of this molecule on T cells and, in parallel, to inhibit iTregs' pro-tumorigenic effects. Given the current scientific understanding that multiple modes of action will be required for effective cancer treatments, our pipeline now includes a number of distinct oncology product candidates, including the two being disclosed today, further attesting to the predictive strength of our in silico approach to drug discovery."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Achieves Third Preclinical Milestone
Company achieves milestone in cancer immunotherapy collaboration with Bayer.
Saturday, December 12, 2015
Compugen Discloses New Results Supporting CGEN-15052
Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City.
Thursday, September 17, 2015
Compugen Obtains Rights to Use Biological Systems and Materials
Additional capabilities anticipated to enhance research and development of Compugen’s immuno-oncology programs.
Wednesday, April 15, 2015
Compugen Announces Planned Relocation of Headquarters to Larger Facilities
New facilities double available space for corporate offices and research and discovery in Israel.
Wednesday, March 25, 2015
Compugen Expands and Strengthens Business Development Team
Felix Karim, PhD, joins Company as Vice President Corporate & Business Development.
Tuesday, March 10, 2015
Compugen Discloses Initial Experimental Results for Predicted ADC Targets
Pipeline program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs.
Tuesday, January 06, 2015
Compugen Announces Presentations of Results for CGEN-15001
Data indicating novel mechanism of action for CGEN-15001 in maintaining long-term therapeutic effect presented at International Conference on Immune Tolerance in Amsterdam.
Wednesday, October 01, 2014
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Incorporation of algorithms modeling additional biological phenomena leads to predictive discovery of four potential immunomodulatory targets.
Tuesday, July 15, 2014
Compugen Reports Fourth Quarter and Calendar 2013 Results
Company discloses key 2014 corporate objectives.
Wednesday, February 12, 2014
Compugen Announces Addition of Prof. Drew Pardoll to its SAB
Prof. Pardoll is a world leader in immuno-oncology research and in the development of novel cancer therapeutics.
Wednesday, January 22, 2014
Compugen Discloses Discovery of Five Potential Cancer Targets for ADC Therapy
ADC target discovery is company’s second focused discovery program utilizing its in silico predictive discovery infrastructure.
Thursday, December 12, 2013
Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model
Short-term administration of CGEN-15001 shown to provide long-term prevention of disease development.
Friday, October 11, 2013
Compugen Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types
CGEN-15049 immune checkpoint protein expressed on wide variety of cancers.
Thursday, September 26, 2013
Compugen Establishes SAB to Guide Pipeline Program Development
Key opinion leaders to advise Company on research and development involving therapeutic product candidates in the fields of immunology and oncology.
Tuesday, August 27, 2013
Compugen Announces Collaboration and License Agreement with Bayer
Compugen to hold 2nd Quarter Conference Call August 7, 2013.
Tuesday, August 06, 2013
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos